AP News

News Summary: Actavis to buy Forest Labs for $25B

BIG DEAL: Ireland's Actavis is offering about $25 billion to buy Forest Laboratories of New York Inc. and leapfrog to become the world's No. 15 drugmaker by revenue.

THE RATIONALE: Actavis, which sells hundreds of generic, brand-name and nonprescription medicines, wants more new brand-name drugs to add to its portfolio. Forest has them, along with the big network of U.S. sales reps targeting family doctors that Actavis lacks.

NEW MODEL: Actavis, billed as a specialty drugmaker, now will have a good mix of primary care drugs and medicines for more complex disorders, plus it's developing similar versions of biologic drugs.

We Almost Lost the Nasdaq

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus